Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer

Huang,Xiaodong; Yang,Yujie; Yang,Chao; Li,Huali; Cheng,Huangrong; Zheng,Yongbin

doi:10.3892/ol.2020.11489

Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer

Authors:
- Xiaodong Huang
- Yujie Yang
- Chao Yang
- Huali Li
- Huangrong Cheng
- Yongbin Zheng
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: March 27, 2020 https://doi.org/10.3892/ol.2020.11489
Pages: 3751-3760
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most common carcinomas with high morbidity and mortality worldwide. However, the underlying molecular mechanisms of CRC are unclear. The aim of the present study was to establish the role that overexpression of LBX2 serves in CRC and to investigate the associated biological pathways. The difference in the expression levels of LBX2 between CRC tissues and adjacent normal colorectal tissues was assessed using the Oncomine database and Tumor Immune Estimation Resource. The expression levels of LBX2 and its prognostic significance in CRC were analyzed using a t‑test and χ2 test using data from The Cancer Genome Atlas database. The Kaplan‑Meier method and Cox regression analysis were used to estimate the prognostic value of LBX2 in CRC. Furthermore, the potential mechanisms of LBX2 dysregulation and its underlying molecular mechanisms in CRC were investigated using Gene Set Enrichment Analysis (GSEA). LBX2 expression levels were significantly upregulated in CRC samples compared with corresponding normal colorectal tissues (P<0.05). LBX2 upregulation was correlated with advanced tumor stage (III or IV), vascular invasion, lymphatic invasion and the male sex (all P<0.05). Kaplan‑Meier analyses showed that high expression levels of LBX2 were associated with a less favorable overall survival (OS) and disease‑free survival (DFS) in CRC (all P<0.05). Multivariate analyses further confirmed that LBX2 upregulation was an independent indicator of less favorable OS and DFS (all P<0.05). In addition, LBX2 DNA hypomethylation and microRNA (miR)‑378a‑3p downregulation correlated with LBX2 upregulation in CRC (all P<0.05). The downregulation of miR‑378a‑3p in CRC was also significantly associated with less favorable OS and DFS, as demonstrated using Kaplan‑Meier analyses (all P<0.05). Moreover, GSEA indicated that ‘VEGF signaling’, ‘Cell adhesion molecules CAMs’, ‘Toll‑like receptor signaling’ and ‘Natural killer cell‑mediated cytotoxicity’ signaling pathways were enriched in the high LBX2 expressing cohort (all P<0.05). Thus, overexpression of LBX2 may be associated with the development of CRC and may serve as a novel prognostic marker and therapeutic target in CRC. The mechanisms of LBX2 upregulation in CRC are possibly associated with LBX2 DNA hypomethylation and miR‑378a‑3p downregulation. The potential mechanisms of LBX2 upregulation in CRC might be regulated via the ‘Cell adhesion molecules CAMs’, ‘Toll‑like receptor signaling’ and ‘Natural killer cell‑mediated cytotoxicity’ signaling pathways.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas Network, . Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
4	Mogensen MB, Rossing M, Østrup O, Larsen PN, Heiberg Engel PJ, Jørgensen LN, Hogdall EV, Eriksen J, Ibsen P, Jess P, et al: Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. BMC Cancer. 18:7522018. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Fang H, Cheng Y, Li L, Sun X, Fu T, Huang P, Zhang A, Feng Z, Li C, et al: The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. Carcinogenesis. 39:708–718. 2018. View Article : Google Scholar : PubMed/NCBI
6	Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, et al: Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 8:730–749. 2018. View Article : Google Scholar : PubMed/NCBI
7	Wang J, Luo J, Chen Q, Wang X, He J, Zhang W, Yin Z, Zheng F, Pan H, Li T, et al: Identification of LBX2 as a novel causal gene of atrial septal defect. Int J Cardiol. 265:188–194. 2018. View Article : Google Scholar : PubMed/NCBI
8	Lou Q, He J, Hu L and Yin Z: Role of lbx2 in the noncanonical Wnt signaling pathway for convergence and extension movements and hypaxial myogenesis in zebrafish. Biochim Biophys Acta. 1823:1024–1032. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lu FI, Sun YH, Wei CY, Thisse C and Thisse B: Tissue-specific derepression of TCF/LEF controls the activity of the Wnt/β-catenin pathway. Nat Commun. 5:53682014. View Article : Google Scholar : PubMed/NCBI
10	Ochi H and Westerfield M: Lbx2 regulates formation of myofibrils. BMC Dev Biol. 9:132009. View Article : Google Scholar : PubMed/NCBI
11	Wang J, Song J, Gao Z, Huo X, Zhang Y, Wang W, Qi J and Zheng S: Analysis of gene expression profiles of non-small cell lung cancer at different stages reveals significantly altered biological functions and candidate genes. Oncol Rep. 37:1736–1746. 2017. View Article : Google Scholar : PubMed/NCBI
12	Bell A, Bell D, Weber RS and El-Naggar AK: CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer. 117:2898–2909. 2011. View Article : Google Scholar : PubMed/NCBI
13	Villarese P, Lours C, Trinquand A, Le Noir S, Belhocine M, Lhermitte L, Cieslak A, Tesio M, Petit A, LeLorch M, et al: TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome. Leukemia. 32:61–71. 2018. View Article : Google Scholar : PubMed/NCBI
14	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
15	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
16	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clinical cancer research : an official journal of the American Association for Cancer Research. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
17	Weiser MR: AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI
18	Punt CJA, Koopman M and Vermeulen L: From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 14:235–246. 2017. View Article : Google Scholar : PubMed/NCBI
19	Sveen A, Kopetz S and Lothe RA: Biomarker-guided therapy for colorectal cancer: Strength in complexity. Nat Rev Clin Oncol. 17:11–32. 2020. View Article : Google Scholar : PubMed/NCBI
20	Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 27:872–877. 2009. View Article : Google Scholar : PubMed/NCBI
21	Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, Yaeger R, Saltz L, Smith JJ, Nash GM, et al: Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 4:309–315. 2018. View Article : Google Scholar : PubMed/NCBI
22	Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, Noshiro H and Miyazaki K: Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol. 17:2349–2356. 2010. View Article : Google Scholar : PubMed/NCBI
23	Fletcher RH: Carcinoembryonic antigen. Ann Intern Med. 104:66–73. 1986. View Article : Google Scholar : PubMed/NCBI
24	Das PM and Singal R: DNA methylation and cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI
25	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
26	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ding N, Sun X, Wang T, Huang L, Wen J and Zhou Y: miR 378a 3p exerts tumor suppressive function on the tumorigenesis of esophageal squamous cell carcinoma by targeting Rab10. Int J Mol Med. 42:381–391. 2018.PubMed/NCBI
28	Li H, Dai S, Zhen T, Shi H, Zhang F, Yang Y, Kang L, Liang Y and Han A: Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer. 50:1207–1221. 2014. View Article : Google Scholar : PubMed/NCBI
29	Valentino A, Calarco A, Di Salle A, Finicelli M, Crispi S, Calogero RA, Riccardo F, Sciarra A, Gentilucci A, Galderisi U, et al: Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: Molecular basis and pathophysiological consequences. Oncogene. 36:6030–6040. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zhang G-J, Zhou H, Xiao H-X, Li Y and Zhou T: MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 14:1092014. View Article : Google Scholar : PubMed/NCBI
31	Winder T and Lenz H-J: Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
32	Yang LC, Lai CY, Hsieh CC and Lin WC: Natural killer cell-mediated anticancer effects of an arabinogalactan derived from rice hull in CT26 colon cancer-bearing mice. Int J Biol Macromol. 124:368–376. 2019. View Article : Google Scholar : PubMed/NCBI
33	Paschos KA, Canovas D and Bird NC: The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 21:665–674. 2009. View Article : Google Scholar : PubMed/NCBI
34	Moradi-Marjaneh R, Hassanian SM, Fiuji H, Soleimanpour S, Ferns GA, Avan A and Khazaei M: Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer. J Cell Physiol. 233:5613–5622. 2018. View Article : Google Scholar : PubMed/NCBI